The next wave of cancer imaging may involve molecular imaging agents that detect the angiogenesis of many malignant cancers. Protein biomarkers, for instance, may indicate tumour angiogenesis in cancer patients.
This will allow imaging of quantitative changes in the tumour vasculature in cancer patients. Integrins αvβ3 and αvβ5 are heterodimeric transmembrane proteins. They are key mediators of tumour growth, invasion and angiogenesis.